Cagrilintide: Appetite Control & Weight Management
A solo explainer in which the host covers how cagrilintide is said to work, how it differs from GLP drugs, and his views on dosing, stacking and lifestyle.
With Matthew
Key moments
Tap a moment to play the video from there.
- 1:04What cagrilintide isMatthew describes it as an analog of amylin, which is made alongside insulin, and mentions research interest in the liver, heart and Alzheimer's.
- 1:50How it worksHe says it binds amylin receptors in the hypothalamus, slows stomach emptying and reduces glucagon after meals.
- 2:57GLPs versus cagrilintideHe contrasts semaglutide, tirzepatide and retatrutide by receptor count and says cagrilintide acts on a different pathway, which opens up combinations.
- 4:36Cautions and contraindicationsHe lists nausea, low blood sugar, diabetic medication and organ issues as cautions, and type 1 diabetes and pregnancy as contraindications.
- 5:55Research dosing and cyclingHe describes starting at 600 micrograms weekly, raising the dose every two to four weeks, and cycling two to three months on with a month off.
- 7:19Peptides to stack with itHe suggests a GLP, AOD-9604, growth hormone peptides, MOTS-c, 5-amino-1MQ and IGF-1 LR3.
- 8:59Supplements to pairHe lists bitters, collagen peptides, a multivitamin, charcoal, a testosterone booster, and NAD and glutathione support, citing the risk of malnutrition on appetite suppressants.
- 10:18Lifestyle toolsHe recommends fasting with a meat-based diet, corrective exercise, hot and cold therapy, lymphatic massage and red light therapy.
- 11:57Pros and consHe names a different pathway, combinability and weekly dosing as pros, and limited long-term knowledge as a con.
- 12:50Matthew's overall opinionHe says he would start with retatrutide and consider cagrilintide only if appetite stayed uncontrollable.
What the video says
Matthew, host of the Peptide Insights channel, gives a solo overview of cagrilintide. He opens by saying he is not a licensed professional and that the video is educational and for entertainment. He describes cagrilintide as an analog of amylin, a hormone made alongside insulin, and says it is being researched for weight control, blood sugar management, and possible benefits for the liver, heart and brain.
On mechanism, Matthew says cagrilintide binds amylin receptors in the hypothalamus to create a feeling of fullness, slows how fast food leaves the stomach, and lowers glucagon after meals. He then compares it with semaglutide, tirzepatide and retatrutide, which he describes as acting on one, two and three receptors respectively. In his account, cagrilintide is not a GLP because it works on a different pathway, which is why he thinks it could be combined with those drugs. He lists the cautions he has seen: nausea, diarrhea and stomach discomfort, low blood sugar, diabetic medication, and pancreatic, kidney or stomach problems. He lists type 1 diabetes and pregnancy as contraindications.
The dosing section is drawn from Reddit forums, professionals and research articles rather than clinical trials. Matthew describes a range from 600 micrograms to 4.5 mg, starting at 600 micrograms once a week and raising the dose every two to four weeks. He suggests cycles of two to three months with at least a one month break. He says the goal is to build habits and reach a healthy weight, not to use the peptide year round. The captions around these numbers are garbled, so the figures are worth checking against the video.
The rest of the talk covers what he would stack with it. Peptides include a GLP, AOD-9604, growth hormone peptides, MOTS-c, 5-amino-1MQ and IGF-1 LR3. He also names supplements and lifestyle tools such as a meat-based diet with fasting, exercise, hot and cold therapy, lymphatic massage and red light therapy. He closes with pros and cons. His personal view is that he would try retatrutide first and add cagrilintide only if appetite stayed uncontrollable.
On each compound
Cagrilintide1:04
Matthew describes it as an amylin analog that increases fullness, slows stomach emptying and lowers glucagon after meals. He gives a research dose range of 600 micrograms to 4.5 mg weekly and calls it a new peptide with unknown long-term effects.
See how your DNA reads CagrilintideSemaglutide2:57
Matthew describes it as working on a single receptor, the GLP receptor, and names it as a GLP that could be combined with cagrilintide.
See how your DNA reads SemaglutideTirzepatide2:57
Matthew says it works on two receptors, GLP and GIP, and lists it among the GLPs he would pair with cagrilintide.
See how your DNA reads TirzepatideRetatrutide2:57
Matthew calls it the most potent of the three GLPs because it acts on three receptors. He says he would start with it ahead of cagrilintide for weight loss.
See how your DNA reads RetatrutideAOD-96047:43
Matthew says it is essentially the same peptide as Frag 176-191 and that it is stronger for fat burning, whereas he sees cagrilintide as more about appetite and weight control.
See how your DNA reads AOD-9604MOTS-c8:13
Matthew calls it an exercise-induced peptide and says it may help metabolic and mitochondrial health. The captions render the name as "Mat C", so this identification is inferred.
See how your DNA reads MOTS-cIGF-1 LR38:45
Matthew lists it as a muscle-building and fat-burning peptide that he would consider adding to a stack.
See how your DNA reads IGF-1 LR3What this video doesn’t settle
- The dosing, cycling and stacking suggestions come from forums and the host's own reading, with no clinical trial data presented.
- Matthew says little is known about cagrilintide, especially its long-term effects.
- The claims about liver, heart and brain protection are stated as research interest without any studies being cited.
Questions this video answers
How does cagrilintide work according to this video?
Matthew says it is an amylin analog that binds amylin receptors in the hypothalamus to create fullness. He adds that it slows how fast food leaves the stomach and lowers glucagon after meals. He links these effects to better weight and blood sugar control.
Is cagrilintide a GLP-1 drug?
Matthew says it is not a GLP because it acts on the amylin receptor rather than GLP receptors. He contrasts it with semaglutide, tirzepatide and retatrutide. He argues the different pathway makes combinations possible.
What side effects and cautions does Matthew mention for cagrilintide?
He names nausea, diarrhea and stomach discomfort as common. He also cautions people with low blood sugar, people on diabetic medication, and those with pancreatic, kidney or stomach issues. He lists type 1 diabetes and pregnancy as contraindications.
What dosing and cycling does Matthew describe for cagrilintide?
He describes a start of 600 micrograms once a week, with increases every two to four weeks and a ceiling of 4.5 mg. He suggests cycles of two to three months with at least a one month break. He says he took these figures from forums, professionals and research articles, not from clinical guidance.
Would Matthew use cagrilintide first for weight loss?
No. He says he would start with retatrutide, then add peptides such as AOD or growth hormone peptides. He would consider cagrilintide only if he were still not losing weight and had uncontrollable appetite.
Video by Peptide Insights on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
